降压治疗时家庭、动态血压变化与心血管疾病生物标记物改变相关

该研究评估降压治疗时，除了诊室血压，家庭血压、动态血压监测（ambulatory blood pressure monito-ring，ABPM）是否能预测心血管疾病生物标志物的变化。方法：入选高血压患者252例，平均年龄68岁，男性占41％，用坎地沙坦（±噻嗪类利尿剂）治疗6月，比较治疗前后诊室血压、家庭血压、ABPM和心血管疾病生物标志物[尿白蛋白排泄率（urinary albumin excretion，uAE）和脑钠尿肽]的变化情况。

Device-Based Treatment in Hypertension:At the Forefront of Renal Denervation

Percutaneous renal denervation is a novel device therapy that modifies the circulatory regulatory system and has received considerable attention recently.This treatment partially blocks the renal sympathetic nervous system,which is an organ-connecting pathway between the brain and the kidney.Denervation techniques currently under clinical investigation include radiofrequency,ultrasonic,and chemical ablation with alcohol,all of which are executed through transcatheter access to the renal artery.All recently published randomized sham-controlled trials have shown a clear antihypertensive effect of renal denervation over 24 hours,including during the nighttime and early morning.This treatment has promise in the management of poorly controlled hypertension as well as in the prevention of the development or aggravation of arrhythmias and heart failure.